ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?

Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.

Zacks Investment Research • Oct 21, 2026

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.

Business Wire • Oct 20, 2026

Zoetis Appoints Iris Knobloch to its Board of Directors

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of.

Business Wire • Oct 13, 2026

Top 50 High-Quality Dividend Growth Stocks For October 2026

I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.

Seeking Alpha • Oct 11, 2026

10 Dividend Growth Stocks: October 2026

In this monthly series, I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. This month's screen targets dividend growth stocks with Dividend Safety scores ≥8.0, forward yields ≥2.5%, and prices at or below fair value. An equally weighted portfolio of the top 10 stocks yields 2.8% but would have underperformed SPY over the past 5 years.

Seeking Alpha • Oct 12, 2026

Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know

In the most recent trading session, Zoetis (ZTS) closed at $74.81, indicating a +2.37% shift from the previous trading day.

Zacks Investment Research • Oct 9, 2026

A Once-in-a-Decade Opportunity: 2 Magnificent Dividend Stocks Down 34% to 52% I'm Buying Right Now

Both stocks are home to niche-leading businesses. However, each has run into some cyclicality in sales.

The Motley Fool • Oct 9, 2026

Zoetis Declares Fourth Quarter 2026 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company's common stock as of the close of business on Friday, October 30, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a leg.

Business Wire • Oct 8, 2026

New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows that not all heartworm preventives perform equally against these resistant isolates. Macrocyclic lactone (ML) resistance means some heartworm isolates are less sensitive to the drug class used in today's heartworm disease preventives. As ML resistance continues to challenge heartworm prevention, veterinarians need data th.

Business Wire • Oct 6, 2026

Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why

Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.

Zacks Investment Research • Oct 1, 2026